Orthologic Corp.

Development of drugs for soft tissue and bone repair, e.g. cure of diabetic foot ulcer

OrthoLogic Corporation is a drug development company and was incorporated as a Delaware corporation in July 1987. In November 2003, OrthoLogic sold the medical device business and concentrated on the development of future biotechnical therapeuticals.
In August 2004, OrthoLogic Inc. purchased all of the assets and intellectual property of Chrysalis Biotechnology Inc.

1275 West Washington
Tempe, AZ 85281
USA
Phone: +1-800-937-5520
+1-602-286-5520

Chrysalin® is a 23-amino acid synthetic peptide that constitutes the basis molecule for several therapeutic products targeted at soft tissue and bone repair. The Chrysalin® molecule is a receptor-binding domain of the human thrombin molecule that regulates blood clotting and forwards the natural cascade of healing events in soft tissue and bone repair.
Chrysalin® mimics specific attributes of the thrombin molecule and so stimulates indirectly the body’s natural healing processes.

Potential medical applications for Chrysalin® are bone fracture repair, dermal wound healing, cartilage defect repair, spine fusion, cardiovascular repair, dental bone repair and ligament and tendon repair.

OrthoLogic undertakes clinical trials for 3 Chrysalin® products for fracture repair, dermal wound healing and spine fusion.
Chrysalin® is in Phase I/II human clinical trial for the application of diabetic foot ulcer. The application for cartilage defect repair, cardiovascular repair, dental bone repair, ligament and tendon repair are tested in preclinical studies.

In May 2005, a phase III human clinical trial was completed for the indication of Chrysalin® for the treatment of unstable and/or displaced distal radius (wrist) factures. OrthoLogic expects to release initial efficacy results in 2006.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.